Offer - Urjas Oil for just ₹ 1 X
Eurepa MF 1 Tablet, a prescription drug, is manufactured in various forms such as Tablet. Other than this, Eurepa MF 1 Tablet has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Eurepa MF 1 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. This information has been provided in detail in the dosage section.
Eurepa MF 1 Tablet also has some side effects, the most common being Stomach Upset, Difficulty urinating. Apart from the aforementioned side effects, Eurepa MF 1 Tablet can also lead to other problems, which have been listed below. Normally, these side effects of Eurepa MF 1 Tablet are not long lasting and go away when the treatment is finished. However, if these continue for a longer time, consult your doctor right away.
In addition, Eurepa MF 1 Tablet's effect is Severe during pregnancy and Severe for lactating mothers. Warnings related to Eurepa MF 1 Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Eurepa MF 1 Tablet is not recommended if you suffer from certain medical conditions as it can have adverse effects. Congestive Heart Failure (CHF), Anemia, Shock are examples of such conditions. Other conditions have been mentioned below in the Eurepa MF 1 Tablet contraindications section.
Additionally, Eurepa MF 1 Tablet may also adversely react with other medicines. Refer to the list below for further details.
In addition to these precautions, you may also note that Eurepa MF 1 Tablet is safe while driving, and is is addictive in nature.
Eurepa MF 1 Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Eurepa MF 1 Tablet safe for pregnant women?
Eurepa Mf has many dangerous side effects in pregnant women. If you are pregnant, do not consume Eurepa Mf without medical advice.
Is the use of Eurepa MF 1 Tablet safe during breastfeeding?
Women who are breastfeeding, may experience serious side effects after taking Eurepa Mf. So it is adviced to consult the doctor before using it.
What is the effect of Eurepa MF 1 Tablet on the Kidneys?
Kidney can be affected by Eurepa Mf. If you experience any unwanted effects of this drug, stop taking it. You should take it again only after medical advice.
What is the effect of Eurepa MF 1 Tablet on the Liver?
There may be an adverse effect on the liver after taking Eurepa Mf. If you observe any side effects on your body then stop taking this drug. Take this medicine again only if your doctor advises you to do so.
What is the effect of Eurepa MF 1 Tablet on the Heart?
Eurepa Mf is rarely harmful for the heart.
Eurepa MF 1 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Eurepa MF 1 Tablet unless your doctor advises you to do so -
Is this Eurepa MF 1 Tablet habit forming or addictive?
Eurepa MF 1 Tablet is not addictive in nature.
Interaction between Food and Eurepa MF 1 Tablet
Due to the absence of research, it is difficult to say how Eurepa MF 1 Tablet and food will interact.
Interaction between Alcohol and Eurepa MF 1 Tablet
Consult your doctor before consuming alcohol while taking Eurepa MF 1 Tablet as it can have severe side effects.
Yes, you can take Eurepa Mf with a beta-blocker. People with diabetes tend to develop heart disease or stroke at an earlier age than the general population. One reason for this is that high glucose levels increase your risk of high blood pressure (hypertension). No harmful interactions are seen between them. However, a recent study suggests that beta-blockers can decrease the plasma level of Eurepa Mf and long-term use can increase lactic acid and uric acid in the blood.
Yes, Eurepa Mf can be taken with the statin. There is no serious or harmful interaction have been observed between them. Some studies say that it's possible your blood sugar (blood glucose) level may increase when you take a statin, which may lead to developing type 2 diabetes. The risk is small but important enough that the Food and Drug Administration (FDA) has issued a warning on statin labels regarding blood glucose levels and diabetes.
Yes, Eurepa Mf is safe to use, many people have side effects at first, they usually diminish and then go away completely in a few weeks. A few people find they cannot tolerate metformin, there are other drugs but metformin is usually the first choice. It is very safe
Lactic acidosis associated with Eurepa Mf treatment is a rare but fatal adverse effect. Lactic acidosis appears to result from biguanide interference causing an increase in production and decrease in clearance of lactate leading to higher cellular lactate levels. A decrease in pyruvate carboxylase activity, the rate-limiting enzyme in the formation of glucose from lactate, can also decrease hepatic metabolism of lactate. leading to increasing lactic acidosis. Signs and symptoms of Eurepa Mf induced lactic acidosis are nonspecific and include anorexia, nausea, vomiting, altered level of consciousness, hyperpnoea, abdominal pain, and thirst.
Eurepa Mf is not a known cause of alopecia (hair loss). However, the conditions treated by Eurepa Mf type 2 diabetes and PCOS, often list hair loss as a possible symptom.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Prandin® (repaglinide)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 273